Oral drug delivery company IntelGenx will promote its contract development and manufacturing organization (CDMO) services capabilities using its existing proprietary VersaFilm and VetaFilm oral film technologies at CPhI North America taking place on April 30-May 2, 2019 in Chicago, IL.
 
VersaFilm and VetaFilm are IntelGenx’s proprietary oral drug delivery technology platforms for human and veterinary applications, respectively. They enable the development of oral films with potential to improve absorption, accelerate onset of action, reduce side effects, ease administration and improve patient compliance.
 
“We are excited to be a part of the CPhI North America,” said Horst Zerbe, president and chief executive officer, IntelGenx. “The conference is an excellent forum to demonstrate to the pharma world our CDMO capabilities and how our oral film technologies can help addressing unmet medical needs.”
 
Established in 2003, IntelGenx is an oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm and VetaFilm technology platforms.
 
IntelGenx’s team provides pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx’s state-of-the-art manufacturing facility, which was established for oral film technology platforms, supports lab-scale to pilot- and commercial-scale production.